It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") for ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Skye ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...